🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareGLP-1 receptor desensitization and tachyphylaxis — looking for input Page 3

GLP-1 receptor desensitization and tachyphylaxis — looking for input

maya_sedona Tue, May 6, 2025 at 2:55 PM 14 replies 1,543 viewsPage 3 of 3
InsuranceTom
Senior Member
1,345
7,890
Mar 2024
Connecticut
May 7, 2025 at 4:58 AM#11
Dr.Martinez said:
Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%),…

Correct, and worth adding that it is reversible. Nothing being described here is a one-way door, which changes how cautious it is reasonable to be.

26 24lisa_labSD, adam_van, Dr.SurgeonPGH and 23 others
Reply Quote Save Share Report
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
May 7, 2025 at 11:31 AM#12
SkepticalSean said:
The mechanism is more central than most summaries suggest.

This is exactly what I could not find anywhere else. Adding it to my notes with a link back to this thread.

27 0BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 24 others
Reply Quote Save Share Report
HealthEcon_DC
Member
567
3,456
Apr 2024
Washington, DC
May 7, 2025 at 6:04 PM#13
Dr.Martinez said:
Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%),…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Filing an objection on the n=1 problem. Personal experience is genuine evidence about one person and very weak evidence about anybody else, and this thread keeps promoting the first into the second.

28 1KevinCompounds, TirzTom, TrialTracker_MD and 25 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
May 8, 2025 at 12:37 AM#14

Adding the numbers, since they settle part of this. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

Last edited: May 8, 2025 at 2:37 AM
29 2bri_stats, pete_manc_UK, anna.melb_AU and 26 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
May 8, 2025 at 7:10 AM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Thread quality here is what the rules are for. Keep it up.

30 3PurityPaulOR, MaxMetOK, MounjBrad and 27 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register